Consumption pattern of gabapentinoids in a tertiary health-care system: a five year study from 2012-2017

Tejus A.; Sharmila Sinha

doi:10.18203/2319-2003.ijbcp20192117

Authors

Tejus A. Department of Pharmacology, Army College of Medical Sciences, Delhi Cantt, New Delhi, India http://orcid.org/0000-0003-3378-2224
Sharmila Sinha Department of Pharmacology, Command Hospital, Lucknow, Uttar Pradesh, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20192117

Keywords:

Consumption pattern, Gabapentinoids, Off label uses

Abstract

Background: Treating chronic pain has always been a great challenge for the treating physician. As the available pharmacotherapy do not always yield desired results, wider armamentarium is needed in tackling the chronic pain. Hence gabapentinoids are often considered, but it has led to widespread off label use of these groups of medications. Hence a study of consumption pattern was carried out to assess the usage of gabapentinoids.

Methods: The consumption pattern of gabapentinoids (gabapentin/ pregabalin/ any combination) was recorded from the medical stores and dispensary of tertiary care teaching hospital.

Results: There is an upward trend in the usage of all gabapentinoids between 2012 to 2017 and pregabalin was seen to be the commonly used gabapentinoid. In the recent years apart from individual gabapentinoids there is a trend favoring use of FDCs of gabapentinoids with nortryptyline and methylcobalamine.

Conclusions: The increase in the usage pattern should alarm us to look into the off label uses of gabapentinoids. As there is a possibility of abuse and misuse of gabapentinoids clear guidelines regarding the same is the need of the hour.

Metrics

Metrics Loading ...

References

Alles SR, Smith PA. Etiology and Pharmacology of Neuropathic Pain. Pharmacol Rev. 2018;70(2):315-47.

Raffaeli W, Arnaudo E. Pain as a disease: an overview. J Pain Res. 2017;10:2003-8. Published 2017 Aug 21.

Andreu V, Arruebo M. Current progress and challenges of nanoparticle based therapeutics in pain management. J Control Release. 2018 Jan 10;269:189-213.

Orr PM, Shank BC, Black AC. The Role of Pain Classification Systems in Pain Management. Crit Care Nurs Clin N Am. 2017;29(4):407-18.

Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, et al. A classification of chronic pain for ICD-11. Pain. 2015 Jun;156(6):1003-7.

Dureja GP, Jain PN, Shetty N, Mandal SP, Prabhoo R, Joshi M, et al. Prevalence of chronic pain, impact on daily life, and treatment practices in India. Pain Pract. 2014 Feb;14(2):E51-62.

Walters JL, Baxter K, Chapman H, Jackson T, Sethuramachandran A, Couldridge M, et al. Chronic Pain and Associated Factors in India and Nepal: A Pilot Study of the Vanderbilt Global Pain Survey. Anesth Analg. 2017;125(5):1616-26.

Fashler SR, Cooper LK, Oosenbrug ED, Burns LC, Razavi S, Goldberg L, et al. Systematic Review of Multidisciplinary Chronic Pain Treatment Facilities. Pain Res Manag. 2016;2016:5960987.

Goodman CW, Brett AS. Gabapentin and Pregabalin for Pain-Is Increased Prescribing a Cause for Concern? N Engl J Med. 2017;377(5):411-4.

Joshi GM. Holistic care in chronic pain. Indian J Pain. 2017;31(2):77-9.

Rosenblatt RA, Catlin M. Opioids for Chronic Pain: First Do No Harm. Ann Fam Med. 2012;10(4):300-1.

Crofford LJ. Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther. 2013;15(Suppl 3):2-10.

Yaksh TL, Wallace MS. Opioids, Analgesia, and Pain Management. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 12th ed. San Diego, California: McGraw-Hill; 2011:481-527.

Dharmshaktu P, Tayal V, Kalra BS. Efficacy of Antidepressants as Analgesics: A Review. J Clin Pharmacol. 2012;52(1):6-17.

Gupta N, Case AA. Adjuvant analgesics. In: Smith HS, Pilitsis JG, editors. The Art and Science of Palliative Medicine. 1st Ed. New York: AME Publishing Company; 2014:209-222.

Dureja GP, Iyer RN, Das G, Ahdal J, Narang P. Evidence and consensus recommendations for the pharmacological management of pain in India. J Pain Res. 2017;10:709-36.

Wallach JD, Ross JS. Gabapentin Approvals, Off-Label Use, and Lessons for Post-marketing Evaluation Efforts. JAMA. 2018;319(8):776-8.

Morrison EE, Sandilands EA, Webb DJ. Gabapentin and pregabalin: do the benefits outweigh the harms? J R Coll Physicians Edinb. 2017 Dec;47(4):310-3.

Mishra R, Tripathi M, Chandola HC. Comparative clinical study of gabapentin and pregabalin for postoperative analgesia in laparoscopic cholecystectomy. Anesth Essays Res. 2016;10(2):201-6.

Johansen ME. Gabapentinoid Use in the United States 2002 Through 2015. JAMA Intern Med. 2018;178(2):292-4.

Wise J. Gabapentinoids should not be used for chronic low back pain, meta-analysis concludes. BMJ. 2017;358:j3870.

Parsons G. Guide to the management of gabapentinoid misuse. Therapy focus prescriber. 2018;1:25-8.

Vasudevan D, Naik MM, Mukaddam QI. Efficacy and safety of methylcobalamin, alpha lipoic acid and pregabalin combination versus pregabalin monotherapy in improving pain and nerve conduction velocity in type 2 diabetes associated impaired peripheral neuropathic condition. [MAINTAIN]: Results of a pilot study. Ann Indian Acad Neurol. 2014;17(1):19-24.

Saxena AK, Jain P, Dureja GP, Venkitachalam A, Goswami S, Usmani H, et al. Pharmacological management of neuropathic pain in India: A consensus statement from Indian experts. Indian J Pain. 2018;32(3):132-44.

Evoy KE, Morrison MD, Saklad SR. Abuse and Misuse of Pregabalin and Gabapentin. Drugs. 2017 Mar; 77(4):403-26.

Smith RV, Havens JR, Walsh SL. Gabapentin misuse, abuse, and diversion: A systematic review. Addiction (Abingdon, England). 2016;111(7):1160-74.

Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W. Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case–control study. PLoS Med. 2017;14(10):e1002396.